[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566729":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":25,"responsibleParty":41,"collaborators":43,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":25,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":25,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":25,"overallStatus":66,"whyStopped":25,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":25},{"fullName":5,"class":6},"Jemincare","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1：JMKX003142 and itraconazole","EXPERIMENTAL","Interaction between JMKX003142 and itraconazole",[13],"Drug: Cohort 1: JMKX003142 and itraconazole",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2：JMKX003142 and rifampicin","Interaction between JMKX003142 and rifampicin",[18],"Drug: Cohort 2: JMKX003142 and rifampicin",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Cohort 1: JMKX003142 and itraconazole","JMKX003142: Dose: 3 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg itraconazole once: Day8, once only in the morning.\n\nItraconazole：Dose: 200mg once；Day5-Day7 and Day9-Day11, QD",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Cohort 2: JMKX003142 and rifampicin","JMKX003142: Dose: 6 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg rifampicin once: Day14, once only in the morning.\n\nRifampicin：Dose: 600mg once；Day5-Day13 and Day15-Day17, QD",[15],[31],{"name":32,"affiliation":33,"role":34},"Leilei Zhu","Shuguang Hospital Affiliated with Shanghai University of TCM","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Jianping Su","CONTACT","86+15162481262","sujianping@jemincare.com",{"type":42,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[44],{"name":45,"class":6},"Zhejiang Hangyu Pharmaceutical Co., Ltd.","100566729","phase-1-study-to-evaluate-the-drug-drug-interaction-of-jmkx003142-in-healthy-subjects-100566729",false,"NCT06658964","Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy Subjects","A Single-center, Non-randomized, Open-label, Self-controlled Phase 1 Clinical Study to Evaluate Drug-drug Interactions of JMKX003142 Tablets in Healthy Subjects","Inclusion Criteria:\n\n* Fully understand the research content, process, and potential risks of this trial, voluntarily participate in the clinical trial and sign the informed consent,\n* Healthy male and female subjects aged ≥18 years and ≤45 years old, Male weight ≥50kg, female weight ≥45kg, body mass index ≥19 kg\u002Fm2 and ≤28 kg\u002Fm2,\n* The health of the subjects was determined by the investigator based on medical history, physical examination, clinical laboratory examination, and 12-lead electrocardiogram, all of which were determined by the investigator to be normal or not clinically significant.\n\nExclusion Criteria:\n\n* HBV surface antigen, HCV antibody, HIV, or syphilis are positive during screening,\n* At the time of screening, the vital signs are within the following ranges: systolic blood pressure \\\u003C90 mmHg or \\>140 mmHg, diastolic blood pressure \\\u003C50 mmHg or \\>90 mmHg, pulse \\\u003C50 bpm or \\>100 bpm and ear temperature 37.5℃or\\\u003C35℃,\n* More than 5 cigarettes per day during the 3 months prior to screening, Or were unable to quit smoking\u002Fcontaining tobacco products during the trial,\n* Have special requirements for diet and cannot comply with the diet provided and corresponding regulations.",true,"ALL","18 Years","45 Years",{"count":58,"type":59},48,"ESTIMATED","INTERVENTIONAL",[62],"PHASE1","To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of JMKX003142 in healthy subjects.",[65],"ADPKD (autosomal Dominant Polycystic Kidney Disease)","NOT_YET_RECRUITING","2024-10-23",{"date":69,"type":70},"2024-10-26","ACTUAL",{"date":72,"type":59},"2024-11-05",{"date":74,"type":59},"2025-03-21",{"name":5,"class":6}]